Journal Article

Ceftriaxone Compared with Sodium Penicillin G for Treatment of Severe Leptospirosis

Thanachai Panaphut, Somnuek Domrongkitchaiporn, Asda Vibhagool, Bandit Thinkamrop and Wattanachai Susaengrat

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 12, pages 1507-1513
Published in print June 2003 | ISSN: 1058-4838
Published online June 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/375226
Ceftriaxone Compared with Sodium Penicillin G for Treatment of Severe Leptospirosis

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

A prospective, open-label, randomized trial at Khon Kaen Hospital (Thailand) was conducted from July 2000 through December 2001 to compare the clinical efficacies of ceftriaxone and sodium penicillin G for the treatment of severe leptospirosis. A total of 173 patients with severe leptospirosis were randomly assigned to be treated with either intravenous ceftriaxone (1 g daily for 7 days; n = 87) or intravenous sodium penicillin G (1.5 million U every 6 h for 7 days; n = 86). The primary outcome was time to fever resolution. Survival analysis demonstrated that the median duration of fever was 3 days for both groups. Ten patients (5 in each group) died of leptospirosis infection. There were no statistically significant differences in the duration of organ dysfunction. Ceftriaxone and sodium penicillin G were equally effective for the treatment of severe leptospirosis. Once-daily administration and the extended spectrum of ceftriaxone against bacteria provide additional benefits over intravenous penicillin.

Journal Article.  4184 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.